Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA)

Diabetes Care

Volumn 22, Issue 8, 1999, Pages 1347-1353

  Isomaa, Bo ^a   Almgren, Peter ^d   Henricsson, Marianne ^c   Taskinen, Marja Riitta ^b   Tuomi, Tiinamaija ^d   Groop, Leif ^d   Sarelin, Leena ^a  

^a Jakobstad Hospital   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HELSINGBORG HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; PREVALENCE;

AGE OF ONSET; AGED; ALBUMINURIA; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0032801250     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.8.1347     Document Type: Article

References (38)

1. Landin-Olsson M, Palmer JP, Lernmark Å, Blom L, Sundkvist G, Nyström L, Dahlquist G: Predictive value of islet cell and insulin autoantibodies for type 1 (insulin-dependent) diabetes mellitus in a population-based study of newly-diagnosed diabetic and matched control children. Diabetologia 35:1068-1073, 1992
2. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states: sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94:1714-1721, 1994
3. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP: Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycemic agents. Lancet i:1025-1027, 1977
4. Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35:237-241, 1986
5. Landin-Olsson M, Nilsson KO, Lernmark Å, Sundqvist G: Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33:561-568, 1990
6. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Å, Sundqvist G: β-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910, 1993
7. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362, 1993
8. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11:299-303, 1994
9. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R (UKPDS 25): Autoantibodies to islet cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288-1293, 1997
10. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ: GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes Care 18:1557-1565, 1995
11. Alberti KGMM, Zimmet PZ for the WHO consultation: Definition, diagnosis and classification of diabetes mellitus and its complications (Part 1). Diabet Med 15:539-553, 1998
12. Tuomi T, Carlsson Å-L, Li H, Isomaa B, Miettinen A, Nilsson A, Nissén M, Ehrnström B-O, Forsén B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen M-R, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999
13. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissén M, Ehrnström B-O, Forsén B, Isomaa B, Snickars B, Taskinen M-R: Metabolic consequences of a family history of NIDDM (The Botnia Study): evidence for sex-specific parental effects. Diabetes 45:1585-1593, 1996
14. Lehto M, Tuomi T, Mahtani M, Widén E, Forsblom C, Sarelin L, Gullström M, Isomaa B, Lehtovirta M, Hyrkkö A, Kanninen T, Orho M, Manley S, Turner R, Brettin T, Kirby A, Thomas J, Duyk G, Lander E, Taskinen MR, Groop L: Characterization of the MODY3 phenotype, early-onset diabetes caused by an insulin secretion defect. J Clin Invest 99:582-591, 1997
15. Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L, Häggblom M, Groop L: Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 41:467-473, 1998
16. Young M, Boulton A, Macleod A, Williams D, Sonksen P: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150-154, 1993
17. Young MJ, Breddy JL, Veves A, Boulton AJM: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 17:557-560, 1994
18. Forsblom C, Eriksson J, Ekstrand A, Teppo A-M, Taskinen MR, Groop L: Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 38:363-369, 1995
19. Mogensen CE, Keane W, Bennett P, Jerums G, Parving H-H, Passa P, Steffes M, Striker G, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
20. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237-243, 1989
21. Klein R, Klein B, Magli Y, Brothers R, Meuer S, Davis M: An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183-1187, 1986
22. Rose G, Blackburn H: Cardiovascular Survey Methods. WHO Monograph Series, Vol. 56. Geneva, World Health Org., 1968
23. Leng GC, Fowkes FGR, Lee AJ, Dubar J, Housley E, Ruckley CV: Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313:1440-1443, 1996
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifugation. Clin Chem 18:499-502, 1972
25. Reaven GM: Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
26. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
27. Taskinen MR, Lahdenperä S, Syvänne M: New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 28:335-340, 1996
28. Syvänne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl.1):20-23, 1997
29. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR for the United Kingdom Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDR: 23). BMJ 316:823-828, 1998
30. Aromaa A (Ed.): Health, Functional Limitations and Need for Care in Finland: Basic Results From the Mini-Finland Health Survey. Helsinki and Turku. Finland, Publications of the Social Insurance Institution, 1989, AL:32 (English summary)
31. Ziegler D, Gries F, Muhlen H, Rathman W, Spuler M, Lessman F and the DIACAN multicenter study group: Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. Diabetes Metab 19:143-151, 1993
32. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M: Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:89-94, 1995
33. Forsblom C, Groop P-H, Groop L: Low predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 305:1051-1053, 1992
34. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Penttilä I, Pyörälä K: Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 diabetic patients. Diabetologia 33: 237-243, 1990
35. Gall M-A, Hougaard P, Borch-Johnsen, Parving H-H: Risk factors for development of incident and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study BMJ 314:783-788, 1997
36. Groop L, Ekstrand A, Forsblom C, Widén E, Groop P-H, Teppo A-M, Eriksson J: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:642-647, 1993
37. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984
38. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy III: prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984